LARVOL

6.7K posts

LARVOL banner
LARVOL

LARVOL

@Larvol

At the intersection of #AI & #Oncology data. We provide clinical intelligence, trial insights & competitive analysis for #Pharmaceutical & #BioTech.

United States Katılım Nisan 2009
3.6K Takip Edilen8.8K Takipçiler
LARVOL
LARVOL@Larvol·
We asked leading AI models to identify the most anticipated Lung Cancer studies ahead of European Lung Cancer Congress (ELCC) 2026—here’s their combined ranking. Top-ranked: OptiTROP-Lung03 Sac-TMT in previously treated EGFR-mutant advanced NSCLC ranked #1 across models, reflecting strong interest in next-generation targeted approaches and novel payload strategies post–TKI progression. Other highly anticipated trials include: 3082-CL-0101 — setidegrasib in KRAS G12D NSCLC Beamion LUNG-1 — zongertinib in 1L HER2-mutant NSCLC with active brain metastases TOP — osimertinib ± chemotherapy in EGFRm + TP53 co-mutated NSCLC KANDLELIT-001 — MK-1084 + pembrolizumab in KRAS G12C NSCLC The rankings highlight momentum across: ▶️ Next-gen targeted therapies in EGFR, KRAS, and HER2 subsets ▶️ Combination strategies in molecularly defined NSCLC ▶️ CNS-active treatments in driver-mutant disease ▶️ Immunotherapy + targeted combinations in KRAS-driven tumors ▶️ Emerging approaches in SCLC and neuroendocrine tumors Which Lung Cancer study are you watching at ELCC 2026? Explore more insights and conference data from #ELCC26 👉 t.ly/ClEtq #LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @FordePatrick | @CharuAggarwalMD | @HHorinouchi | @ADesaiMD | @diegoadiazg
LARVOL tweet media
English
1
3
7
284
LARVOL
LARVOL@Larvol·
We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by @TumorBoardTues on NSCLC 👉 x.com/TumorBoardTues… Both AI models and clinicians favored HER2-targeted TKI therapy (zongertinib) in the 1L setting for HER2 exon 20–mutant metastatic NSCLC, underscoring the strength of biomarker-driven treatment decisions. AI showed even stronger consensus (~76%) compared to oncologists (63%), reflecting a clear preference for targeted inhibition in this population. Antibody-drug conjugates (T-DXd) received meaningful support from both AI (~20%) and oncologists (~26%), with higher real-world adoption among clinicians highlighting growing confidence in ADCs as an alternative HER2-directed strategy. Immunotherapy alone saw limited selection from both groups (AI ~2% vs oncologists ~10%), consistent with the recognized reduced efficacy of ICIs in oncogene-driven disease with low PD-L1 expression. Overall, AI and oncologists aligned closely on prioritizing HER2-directed therapies, with differences reflecting evolving clinical adoption patterns and familiarity with newer agents in this rapidly shifting treatment landscape. #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #NSCLC #LungCancer #LCSM | @StephenVLiu | @Tony_Calles | @FordePatrick | @ADesaiMD | @lungoncdoc
LARVOL tweet media
#TumorBoardTuesday@TumorBoardTues

@riess_md @JackieAredoMD @IntegrityCE #PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT26 B4⃣@riess_md & @JackieAredoMD 🗣️HER2🎯💊in mNSCLC, test your🧠with these 2❓ 🤔A 48 YO🚫smoker♂️is Dx w/NSCLC adenoCa (liver &🦴mets) 🔬PD-L1<1% 🧬NGS shows HER2 Ex20ins mutation ➡️Which do you offer as 1L tx❓

English
0
2
5
364
LARVOL
LARVOL@Larvol·
We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Dr. Ben Derman (@bdermanmd) on Multiple Myeloma 👉 x.com/bdermanmd/stat… Both AI models and clinicians strongly favored CAR T (cilta-cel) after progression on Dara-Rd, underscoring the clear shift toward cellular therapies in early relapse and the perceived depth and durability of response in this setting. Bispecific antibodies (e.g., teclistamab ± daratumumab) saw consistent, moderate support from both AI (~21%) and oncologists (~22%), reflecting their growing role—though still generally positioned behind CAR T in sequencing. Overall, AI and oncologists aligned closely on the dominance of next-generation immunotherapies, with CAR T emerging as the clear standard in this scenario, while differences reflect how quickly clinical practice is evolving beyond legacy treatment paradigms. #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MultipleMyeloma #Myeloma #MMSM | @VincentRK | @RahulBanerjeeMD | @HadidiSamer | @Abdallah81MD
LARVOL tweet media
Ben Derman@bdermanmd

For a contemporary patient with myeloma that receives Dara-VRd induction, forgoes ASCT, and proceeds with maintenance, what would you recommend at relapse (assume Dara-R resistance)?

English
0
4
9
866
LARVOL
LARVOL@Larvol·
Ahead of the European Lung Cancer Congress (ELCC) 2026, we asked leading AI models to forecast outcomes for high-impact lung cancer trials, before any numerical results are released. We compared predictions across models to generate an AI consensus on expected efficacy signals across NSCLC and ES-SCLC, covering key endpoints including PFS, OS, and EFS. Each forecast includes: hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, and a predicted Kaplan–Meier curve showing how outcomes may separate over time. Highlights: NSCLC HARMONi: Ivonescimab + chemotherapy projected strong PFS benefit ▶️ AI consensus PFS HR: 0.36 KEYNOTE-671: Perioperative pembrolizumab expected to sustain benefit at long-term follow-up ▶️ EFS HR: 0.59 | OS HR: 0.73 TOP: Osimertinib + chemotherapy predicted to improve outcomes vs osimertinib alone ▶️ PFS HR: 0.65 OptiTROP-Lung03: Sac-TMT projected to show meaningful OS benefit ▶️ OS HR: 0.59 ES-SCLC IMpower133: Long-term follow-up expected to maintain immunotherapy benefit ▶️ OS HR: 0.79 | PFS HR: 0.80 CAPSTONE-1: Adebrelimab + chemotherapy forecast to sustain survival advantage ▶️ OS HR: 0.76 Mixed signals EMPOWER-Lung 1: Cemiplimab monotherapy predicted to maintain durable survival gains ▶️ OS HR: 0.61 LATIFY: Limited benefit expected for ceralasertib + durvalumab ▶️ OS HR: 0.98 (not significant) Across trials, the AI consensus points to continued durability of immunotherapy benefits, incremental gains from combination strategies, and variable outcomes in targeted therapy settings. Which ELCC 2026 results do you expect will beat or fall short of these forecasts? Explore more insights and conference data from #ELCC26 👉 t.ly/ClEtq #LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @Tony_Calles | @FordePatrick | @HHorinouchi | @BalazsHalmosMD | @DrSanjayPopat
LARVOL tweet mediaLARVOL tweet mediaLARVOL tweet mediaLARVOL tweet media
English
1
6
13
2.7K
LARVOL
LARVOL@Larvol·
We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Oncology Brothers (@OncBrothers) on Colorectal Cancer 👉 x.com/OncBrothers/st… Both AI models and clinicians favored dual checkpoint blockade (ipi/nivo), reflecting the strong practice pull of dMMR/MSI-H biology and established first-line immunotherapy benefit in this setting. Interestingly, encorafenib + cetuximab + chemotherapy was chosen more often by clinicians (33%) than AI (8%), suggesting some oncologists place greater weight on the aggressive BRAF V600E biology and visceral disease burden when considering an upfront targeted approach despite concurrent dMMR features. Overall, AI models and oncologists converged on immunotherapy as the leading strategy, while the divergence around BRAF-targeted combinations highlights the ongoing tension between molecularly defined IO benefit and aggressive BRAF-driven disease biology in first-line metastatic CRC. #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ColorectalCancer #CRC #GICSM | @pashtoonkasi | @CathyEngMD | @Erman_Akkus | @GIcancerDoc
LARVOL tweet media
Oncology Brothers@OncBrothers

Denovo metastatic right sided colon cancer with lung and liver involvement. BRAF V600E+ & MLH1 loss of expression. ECOG 0. IO or BRAFi based treatment in 1L? #OncTwitter @GIMedOnc @pashtoonkasi @CathyEngMD @DrR_DUNNE @GillSharlene @NVijayvergiaMD @SKamath_MD #gism

English
1
5
11
966

Keşfet

@FordePatrick @CharuAggarwalMD @HHorinouchi @ADesaiMD @diegoadiazg @TumorBoardTues @StephenVLiu @Tony_Calles